Table 1.
Socio-demographic and clinical information.
| HC (n=25) | CHR (n=21) | FESZ (n=20) | ||
|---|---|---|---|---|
| Mean age (SD) | 21.9 (2.4) | 20.6 (3.7) | 22.4 (4.9) | N.S. |
| Gender (male/female) | 12/13 | 13/8 | 14/6 | N.S. |
| Pre-morbid IQ (oral reading) | 117.7 (14.9) | 115.4 (12.9) | 114.9 (14.9) | N.S. |
| Current IQ | 121.4 (14.5) | 121.4 (11.0) | 106.3 (15.9) | p<0.01 |
| Education (years) | 14.6 (2.0) | 12.9 (2.8) | 13.5 (2.6) | N.S. |
| PSES | 1.7 (1.0) | 1.9 (0.9) | 2.2 (0.95) | N.S. |
| GAF | 84.7 (7.5) | 49.2 (9.8) | 51.7 (13.1) | p<0.01 |
| Time between Ist admission-EEG (years) | N.A. | N.A. | 1.36 (0.6) | N.A. |
| SOPS Total | N.A. | 26 (8.9) | N.A. | N.A. |
| SOPS Positive | N.A. | 11.8 (5.1) | N.A. | N.A. |
| SOPS Negative | N.A. | 14.2 (7.7) | N.A. | N.A. |
| BPRS Total | N.A. | N.A. | 96.0 (12.6) | N.A. |
| BPRS Positive | N.A. | N.A. | 6.9 (3.3) | N.A. |
| BPRS Negative | N.A. | N.A. | 6.1 (2.9) | N.A. |
| Medicated/unmedicated | N.A. | 7/14 | 18/2 | p<0.01 |
| CPZ equivalents | N.A. | 68.6 (51.0) | 334.4 (350.4) | p<0.01 |
| Targets | 35.8 (1.7) | 36.6 (1.9) | 37.6 (1.9) | N.S. |
Values are mean (SD); HC, Healthy controls; CHR, Clinical high risk individuals; FESZ, First episode schizophrenia patients; CPZ, Chlorpromazine; PSES, Parental Socioeconomic Status; N.A., not applicable; N.S., not significant, p >0.05. CPZ equivalents were calculated for subjects on medication (CHR, n=7; FESZ, n=18) (according to Stoll, 2009, and Woods, 2003); Targets, number of targets counted across the classic and novelty oddball tasks.